Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019

IMPORTANCE: Insulin list prices have grown substantially since 2010, but net prices have declined since 2015 because of manufacturer discounts, leading to an increasingly large difference between list and net prices of drugs often called the gross-to-net bubble. It remains unclear to what extent the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Sean R., Gabriel, Nico, Gellad, Walid F., Hernandez, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267767/
https://www.ncbi.nlm.nih.gov/pubmed/37314806
http://dx.doi.org/10.1001/jamanetworkopen.2023.18145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267767/
https://www.ncbi.nlm.nih.gov/pubmed/37314806
http://dx.doi.org/10.1001/jamanetworkopen.2023.18145

Ejemplares similares